Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease
NCT ID: NCT01716637
Last Updated: 2016-05-12
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
12 participants
Study Classification
INTERVENTIONAL
Study Start Date
2010-02-28
Study Completion Date
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
While the cause of AD is still unknown, evidence suggests it develops because of a complex series of events in the brain that occur over time. Two pathways possibly involved in development of AD are inflammation and oxidative stress. Scientists have linked chronic inflammatory events in the brain with the onset and progression of Alzheimer's Disease. Oxidative stress has also been implicated in the pathogenesis of a number of neurological disorders including Alzheimer's Disease.
Etanercept (Enbrel®) is an approved drug for the treatment of several forms of arthritis when administered by injection. Some research suggests that etanercept, when administered by injection into the tissues close to the spinal column (perispinally), may modulate certain aspects of the immune system and provide some beneficial effect for people with Alzheimer's disease. Studies suggest that supplementation with specific nutrients may also have a positive effect in support of cognitive function.
This study will be conducted at one research office with volunteers who have been diagnosed with mild to moderate Alzheimer's disease. Each qualifying participant will be randomly assigned to receive an etanercept injection plus nutritional supplements for 6 weeks followed by a crossover and a washout period of 4 weeks to then receiving nutritional supplements alone or vice versa for another 6 weeks.
Participants will undergo blood and urine safety assessments at the beginning and end of each 6 week treatment period. During 4 of the 6 weekly visits in the treatment period with the injections, you will complete the cognitive tests twice; once before and once 2 hours after the injection. During 4 of the 6 weekly visits in the treatment period without the injections, you will also complete the cognitive tests twice; once before and once 2 hours after being asked to lie down onto a table for 5 minutes. You will be allowed to continue your standard of care for Alzheimer's disease throughout your participation in the study.
Etanercept (Enbrel®) is an approved drug for the treatment of several forms of arthritis when administered by injection. Some research suggests that etanercept, when administered by injection into the tissues close to the spinal column (perispinally), may modulate certain aspects of the immune system and provide some beneficial effect for people with Alzheimer's disease. Studies suggest that supplementation with specific nutrients may also have a positive effect in support of cognitive function.
This study will be conducted at one research office with volunteers who have been diagnosed with mild to moderate Alzheimer's disease. Each qualifying participant will be randomly assigned to receive an etanercept injection plus nutritional supplements for 6 weeks followed by a crossover and a washout period of 4 weeks to then receiving nutritional supplements alone or vice versa for another 6 weeks.
Participants will undergo blood and urine safety assessments at the beginning and end of each 6 week treatment period. During 4 of the 6 weekly visits in the treatment period with the injections, you will complete the cognitive tests twice; once before and once 2 hours after the injection. During 4 of the 6 weekly visits in the treatment period without the injections, you will also complete the cognitive tests twice; once before and once 2 hours after being asked to lie down onto a table for 5 minutes. You will be allowed to continue your standard of care for Alzheimer's disease throughout your participation in the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety of a Strategy Combining Etanercept Administration with Repeated Contrast Ultrasound in Patients with Alzheimer's Disease
NCT06585384
Alzheimer Disease
NOT_YET_RECRUITING
PHASE1
Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease
NCT01669876
Alzheimer Disease
TERMINATED
PHASE2
Examining Neuroinflammation in AlzHeimer's
NCT03548883
Alzheimer Disease, Early-Onset
COMPLETED
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
NCT04971733
Alzheimer Disease
COMPLETED
PHASE1/PHASE2
Curcumin in Patients With Mild to Moderate Alzheimer's Disease
NCT00099710
Alzheimer's Disease
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Alzheimer's Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
Primary Study Purpose
HEALTH_SERVICES_RESEARCH
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Etanercept
25 mg administered weekly for 6 weeks
Group Type
ACTIVE_COMPARATOR
Etanercept
Intervention Type
BIOLOGICAL
Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.
Intervention Type
DIETARY_SUPPLEMENT
Nutritional Supplements
Nutritional supplements administered daily for 6 weeks in each period as well as an additional 12 weeks following visit 15.
Group Type
ACTIVE_COMPARATOR
Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.
Intervention Type
DIETARY_SUPPLEMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Etanercept
Intervention Type
BIOLOGICAL
Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.
Intervention Type
DIETARY_SUPPLEMENT
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Enbrel®
Super Bio-Curcumin
Super Omega-3
Optimized Quercetin
Optimized Resveratrol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is aged 60-85 years
* Subject has a diagnosis of Alzheimer's disease according to the NINCDS- ADRDA criteria (National Institute of Neurological and Communicative Disorders and Stroke NINCDS\] and Alzheimer's Disease and Related Disorders Association \[ADRDA\]).
* Subject is not institutionalized (for example, lives independently, lives independently in a residential home for the elderly, or is a day patient at a care center)
* Subject has a Hachinski Ischemia Score of ≤ 4.
* Subject has a total MoCA score of \< 26 at screening.
* Subject has an MMSE score of 11 to 24 at screening.
* Subject has an ADAS-cog score of 12 to 25 at screening.
* Subject has experienced a gradual and progressive cognitive decline in the 6 months before the screening visit.
* Subject provides informed consent to participate in the study or has a legally acceptable representative who provides consent.
* Subject has a responsible caregiver who consents to supporting the subject in his/her study participation (for example, by accompanying the subject on each study visit).
* Subject is surgically sterile, agrees to use an acceptable method of birth control as defined in section 5.4 or, for females, is post- menopausal.
* Subject agrees to stop taking any vitamin, mineral, or dietary supplements he/she is currently taking that have any components of the nutritional supplements utilized in the study at least 7 days before randomization (Visit 2) and agrees to not use any new vitamin, mineral, or dietary supplement product other than those provided by the investigator until after the subject is discharged from the study.
* Subject has a diagnosis of Alzheimer's disease according to the NINCDS- ADRDA criteria (National Institute of Neurological and Communicative Disorders and Stroke NINCDS\] and Alzheimer's Disease and Related Disorders Association \[ADRDA\]).
* Subject is not institutionalized (for example, lives independently, lives independently in a residential home for the elderly, or is a day patient at a care center)
* Subject has a Hachinski Ischemia Score of ≤ 4.
* Subject has a total MoCA score of \< 26 at screening.
* Subject has an MMSE score of 11 to 24 at screening.
* Subject has an ADAS-cog score of 12 to 25 at screening.
* Subject has experienced a gradual and progressive cognitive decline in the 6 months before the screening visit.
* Subject provides informed consent to participate in the study or has a legally acceptable representative who provides consent.
* Subject has a responsible caregiver who consents to supporting the subject in his/her study participation (for example, by accompanying the subject on each study visit).
* Subject is surgically sterile, agrees to use an acceptable method of birth control as defined in section 5.4 or, for females, is post- menopausal.
* Subject agrees to stop taking any vitamin, mineral, or dietary supplements he/she is currently taking that have any components of the nutritional supplements utilized in the study at least 7 days before randomization (Visit 2) and agrees to not use any new vitamin, mineral, or dietary supplement product other than those provided by the investigator until after the subject is discharged from the study.
Exclusion Criteria
* A neurologic disorder, such as seizures, multiple sclerosis, neurodegenerative disorders (eg, Parkinson's disease), or dementia other than Alzheimer's type (including that caused by small strokes or cerebrovascular disease)
* Cognitive impairment from any condition other than Alzheimer's disease, such as that resulting from acute cerebral trauma, cerebral damage due to a lack of oxygen, infections such as meningitis or AIDS, significant endocrine or metabolic disease, mental retardation, or a brain tumor
* Cardiovascular or cerebrovascular disease, such as congestive heart failure, uncontrolled hypertension (BP ≥ 140/90 mmHg at screening), and a history of stroke
* Renal impairment/disease, defined as serum creatinine \> 1.5 mg/dL
* Hepatic impairment, defined as Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \> 3 times the upper limit of normal OR has a history of a positive blood screen for hepatitis B surface antigen or hepatitis C antibody.
* Type I or II diabetes mellitus
* Significant or uncontrolled psychiatric disease
* Gastrointestinal disease, such as active peptic ulcer, gallstones, gallbladder disease, or biliary tract obstruction, or a history of cholecystectomy
* Hematologic disorders
* Pulmonary or lung disorders
* Immune system disorder, such as HIV/AIDS
* History of cancer within 10 years before screening (except localized skin cancer without metastases or in situ cervical cancer)
* History of chronic or recurrent infection (including tuberculosis) OR, in the 7 days before Visit 2 (randomization), any known infection or body temperature \> 38.6º C (101.5º F)
* Subject is pregnant or breastfeeding at screening.
* Subject has intolerance or allergy to Enbrel®, latex, or any of Enbrel's components.
* Subject is currently consuming more than 6 standard alcoholic beverages a week. A standard alcoholic beverage is defined as 12 ounces of beer, 5 ounces of wine, or 1.5 ounces of liquor.
* Subject is currently taking and unable or unwilling to stop taking anticoagulant or antiplatelet herbs and supplements such as angelica, clove, danshen, garlic, ginger, ginkgo, Panax ginseng, red clover, or willow for at least 7 days before the randomization visit (Visit 2) and throughout the study.
* Subject is currently taking and unable or unwilling to stop taking any of the prohibited medications in protocol section 5.3.2 for at least 7 days before the randomization visit (Visit 2) and throughout the study.
* Subject had major surgery within the 4 weeks before screening.
* Subject has any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the subject or the quality of the study data.
* Subject is participating or has participated in another research study within 30 days before the screening visit
* Subject or subject's caregiver is unable or unwilling to comply with the study procedures.
* Cognitive impairment from any condition other than Alzheimer's disease, such as that resulting from acute cerebral trauma, cerebral damage due to a lack of oxygen, infections such as meningitis or AIDS, significant endocrine or metabolic disease, mental retardation, or a brain tumor
* Cardiovascular or cerebrovascular disease, such as congestive heart failure, uncontrolled hypertension (BP ≥ 140/90 mmHg at screening), and a history of stroke
* Renal impairment/disease, defined as serum creatinine \> 1.5 mg/dL
* Hepatic impairment, defined as Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \> 3 times the upper limit of normal OR has a history of a positive blood screen for hepatitis B surface antigen or hepatitis C antibody.
* Type I or II diabetes mellitus
* Significant or uncontrolled psychiatric disease
* Gastrointestinal disease, such as active peptic ulcer, gallstones, gallbladder disease, or biliary tract obstruction, or a history of cholecystectomy
* Hematologic disorders
* Pulmonary or lung disorders
* Immune system disorder, such as HIV/AIDS
* History of cancer within 10 years before screening (except localized skin cancer without metastases or in situ cervical cancer)
* History of chronic or recurrent infection (including tuberculosis) OR, in the 7 days before Visit 2 (randomization), any known infection or body temperature \> 38.6º C (101.5º F)
* Subject is pregnant or breastfeeding at screening.
* Subject has intolerance or allergy to Enbrel®, latex, or any of Enbrel's components.
* Subject is currently consuming more than 6 standard alcoholic beverages a week. A standard alcoholic beverage is defined as 12 ounces of beer, 5 ounces of wine, or 1.5 ounces of liquor.
* Subject is currently taking and unable or unwilling to stop taking anticoagulant or antiplatelet herbs and supplements such as angelica, clove, danshen, garlic, ginger, ginkgo, Panax ginseng, red clover, or willow for at least 7 days before the randomization visit (Visit 2) and throughout the study.
* Subject is currently taking and unable or unwilling to stop taking any of the prohibited medications in protocol section 5.3.2 for at least 7 days before the randomization visit (Visit 2) and throughout the study.
* Subject had major surgery within the 4 weeks before screening.
* Subject has any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the subject or the quality of the study data.
* Subject is participating or has participated in another research study within 30 days before the screening visit
* Subject or subject's caregiver is unable or unwilling to comply with the study procedures.
Minimum Eligible Age
60 Years
Maximum Eligible Age
85 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Life Extension Foundation Inc.
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul H. Wand, M.D.
Role: PRINCIPAL_INVESTIGATOR
Paul H. Wand M.D., P.A.
Mark L. Brody, M.D.
Role: PRINCIPAL_INVESTIGATOR
Brain Matters Research Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Paul H. Wand M.D., P.A.
Coral Springs, Florida, United States
Site Status
Brain Matters Research
Delray Beach, Florida, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol. 2006 Oct;63(10):1402-8. doi: 10.1001/archneur.63.10.1402.
Reference Type
BACKGROUND
Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol. 1980 May;7(5):486-8. doi: 10.1002/ana.410070516.
Reference Type
BACKGROUND
Centers for Disease Control and Prevention website. CDC Features: Alzheimer's Disease. http://www.cdc.gov/Features/Alzheimers/. 12-15-2008. 6-23-2009.
Reference Type
BACKGROUND
Mrak RE, Griffin WS. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging. 2001 Nov-Dec;22(6):903-8. doi: 10.1016/s0197-4580(01)00287-1.
Reference Type
BACKGROUND
Alzheimer's Disease Education & Referral (ADEAR) Center, National Institutes of Health. Alzheimer's Disease Fact Sheet. 2008.
Reference Type
BACKGROUND
Mrak RE, Griffin WS. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging. 2005 Mar;26(3):349-54. doi: 10.1016/j.neurobiolaging.2004.05.010.
Reference Type
BACKGROUND
Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1200-5. doi: 10.1136/jnnp.74.9.1200.
Reference Type
BACKGROUND
McGeer PL, McGeer EG. Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol. 2002 Dec;8(6):529-38. doi: 10.1080/13550280290100969.
Reference Type
BACKGROUND
Kaur C, Ling EA. Antioxidants and neuroprotection in the adult and developing central nervous system. Curr Med Chem. 2008;15(29):3068-80. doi: 10.2174/092986708786848640.
Reference Type
BACKGROUND
Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed. 2006 Apr 26;8(2):25.
Reference Type
BACKGROUND
Tarkowski E, Liljeroth AM, Minthon L, Tarkowski A, Wallin A, Blennow K. Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull. 2003 Aug 15;61(3):255-60. doi: 10.1016/s0361-9230(03)00088-1.
Reference Type
BACKGROUND
Laws SM, Perneczky R, Wagenpfeil S, Muller U, Forstl H, Martins RN, Kurz A, Riemenschneider M. TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. Hum Mutat. 2005 Jul;26(1):29-35. doi: 10.1002/humu.20180.
Reference Type
BACKGROUND
Tobinick EL, Gross H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol. 2008 Jul 21;8:27. doi: 10.1186/1471-2377-8-27.
Reference Type
BACKGROUND
Becker RE. Modifying clinical trial designs to test treatments for clinical significance in individual patients. Clin Drug Invest 2001:21:727-733.
Reference Type
BACKGROUND
Griffin WS. Perispinal etanercept: potential as an Alzheimer therapeutic. J Neuroinflammation. 2008 Jan 10;5:3. doi: 10.1186/1742-2094-5-3.
Reference Type
BACKGROUND
Tobinick E. Perispinal etanercept for neuroinflammatory disorders. Drug Discov Today. 2009 Feb;14(3-4):168-77. doi: 10.1016/j.drudis.2008.10.005. Epub 2008 Dec 6.
Reference Type
BACKGROUND
Tobinick E. Perispinal etanercept for treatment of Alzheimer's disease. Curr Alzheimer Res. 2007 Dec;4(5):550-2. doi: 10.2174/156720507783018217.
Reference Type
BACKGROUND
Tobinick EL. A critique of intradiscal administration for treatment of radiculopathy. Anesthesiology. 2008 Feb;108(2):334; author reply 335. doi: 10.1097/01.anes.0000300072.56020.10. No abstract available.
Reference Type
BACKGROUND
Tobinick E. Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism. Medscape J Med. 2008 Jun 10;10(6):135.
Reference Type
BACKGROUND
Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med. 2003 Feb;9(1):161-8. doi: 10.1089/107555303321223035.
Reference Type
BACKGROUND
Pendurthi UR, Williams JT, Rao LV. Inhibition of tissue factor gene activation in cultured endothelial cells by curcumin. Suppression of activation of transcription factors Egr-1, AP-1, and NF-kappa B. Arterioscler Thromb Vasc Biol. 1997 Dec;17(12):3406-13. doi: 10.1161/01.atv.17.12.3406.
Reference Type
BACKGROUND
Antony S, Kuttan R, Kuttan G. Immunomodulatory activity of curcumin. Immunol Invest. 1999 Sep-Dec;28(5-6):291-303. doi: 10.3109/08820139909062263.
Reference Type
BACKGROUND
Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA, Sartor RB. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol. 1999 Sep 15;163(6):3474-83.
Reference Type
BACKGROUND
Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001 Nov 1;21(21):8370-7. doi: 10.1523/JNEUROSCI.21-21-08370.2001.
Reference Type
BACKGROUND
Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005 Feb 18;280(7):5892-901. doi: 10.1074/jbc.M404751200. Epub 2004 Dec 7.
Reference Type
BACKGROUND
Ueda H, Yamazaki C, Yamazaki M. Luteolin as an anti-inflammatory and anti-allergic constituent of Perilla frutescens. Biol Pharm Bull. 2002 Sep;25(9):1197-202. doi: 10.1248/bpb.25.1197.
Reference Type
BACKGROUND
Xagorari A, Papapetropoulos A, Mauromatis A, Economou M, Fotsis T, Roussos C. Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. J Pharmacol Exp Ther. 2001 Jan;296(1):181-7.
Reference Type
BACKGROUND
Rezai-Zadeh K, Douglas Shytle R, Bai Y, Tian J, Hou H, Mori T, Zeng J, Obregon D, Town T, Tan J. Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer's disease beta-amyloid production. J Cell Mol Med. 2009 Mar;13(3):574-88. doi: 10.1111/j.1582-4934.2008.00344.x. Epub 2008 Apr 9.
Reference Type
BACKGROUND
Borchers AT, Sakai S, Henderson GL, Harkey MR, Keen CL, Stern JS, Terasawa K, Gershwin ME. Shosaiko-to and other Kampo (Japanese herbal) medicines: a review of their immunomodulatory activities. J Ethnopharmacol. 2000 Nov;73(1-2):1-13. doi: 10.1016/s0378-8741(00)00334-2.
Reference Type
BACKGROUND
Lo CJ, Chiu KC, Fu M, Lo R, Helton S. Fish oil decreases macrophage tumor necrosis factor gene transcription by altering the NF kappa B activity. J Surg Res. 1999 Apr;82(2):216-21. doi: 10.1006/jsre.1998.5524.
Reference Type
BACKGROUND
Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest. 2005 Oct;115(10):2774-83. doi: 10.1172/JCI25420.
Reference Type
BACKGROUND
Yano M, Kishida E, Iwasaki M, Kojo S, Masuzawa Y. Docosahexaenoic acid and vitamin E can reduce human monocytic U937 cell apoptosis induced by tumor necrosis factor. J Nutr. 2000 May;130(5):1095-101. doi: 10.1093/jn/130.5.1095.
Reference Type
BACKGROUND
Calder PC. Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2007 Nov-Dec;77(5-6):327-35. doi: 10.1016/j.plefa.2007.10.015. Epub 2007 Nov 26.
Reference Type
BACKGROUND
Venkatraman JT, Chu WC. Effects of dietary omega-3 and omega-6 lipids and vitamin E on serum cytokines, lipid mediators and anti-DNA antibodies in a mouse model for rheumatoid arthritis. J Am Coll Nutr. 1999 Dec;18(6):602-13. doi: 10.1080/07315724.1999.10718895.
Reference Type
BACKGROUND
Caughey GE, Mantzioris E, Gibson RA, Cleland LG, James MJ. The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr. 1996 Jan;63(1):116-22. doi: 10.1093/ajcn/63.1.116.
Reference Type
BACKGROUND
James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000 Jan;71(1 Suppl):343S-8S. doi: 10.1093/ajcn/71.1.343s.
Reference Type
BACKGROUND
Kotani S, Sakaguchi E, Warashina S, Matsukawa N, Ishikura Y, Kiso Y, Sakakibara M, Yoshimoto T, Guo J, Yamashima T. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res. 2006 Oct;56(2):159-64. doi: 10.1016/j.neures.2006.06.010. Epub 2006 Aug 14.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CL025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
TNF-Alpha Inhibition for Treatment of Alzheimer's Disease
NCT00203359
COMPLETED
PHASE1
Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease
NCT00013923
COMPLETED
PHASE2
A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
NCT01807026
COMPLETED
PHASE1
Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD
NCT02221622
COMPLETED
PHASE1
TNF-Alpha Inhibition for Treatment of Alzheimer's Disease
NCT00203320
COMPLETED
PHASE1
Safety and Tolerability of Etanercept in Alzheimer's Disease
NCT01068353
COMPLETED
PHASE2
Efficacy of HellenCare in Early-Stage Alzheimer's Disease
NCT06895525
NOT_YET_RECRUITING
NA
Evaluating Simvastatin's Potential Role in Therapy
NCT00486044
COMPLETED
PHASE2
A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease
NCT02353598
COMPLETED
PHASE1
Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers
NCT01005862
COMPLETED
PHASE1
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
NCT03114657
TERMINATED
PHASE3
A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease
NCT00455000
COMPLETED
PHASE1
Effects of an Anti-Inflammatory Drug in Alzheimer's Disease
NCT00013650
COMPLETED
PHASE1
BRain Energy Activation With Ketones to Prevent Alzheimer's Disease
NCT04466735
COMPLETED
NA
To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease
NCT01125683
TERMINATED
PHASE2
Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease
NCT01661673
COMPLETED
PHASE2
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
NCT06745583
RECRUITING
PHASE2
Effect of LY2062430 on the Progression of Alzheimer's Disease
NCT00905372
COMPLETED
PHASE3
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
NCT02565511
TERMINATED
PHASE2/PHASE3
Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease
NCT00733642
COMPLETED
PHASE1
Efficacy and Safety of Curcumin Formulation in Alzheimer's Disease
NCT01001637
TERMINATED
NA
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
NCT02670083
TERMINATED
PHASE3
Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease
NCT03008161
COMPLETED
PHASE1
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
NCT06189963
RECRUITING
PHASE1/PHASE2
Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
NCT04500847
RECRUITING
PHASE1